期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 53, 期 7, 页码 557-573出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2008.10.041
关键词
heart; failure; decompensated; acute; syndromes
资金
- Abbott
- Astellas
- Bayer
- AstraZeneca
- Corthera
- Debiopharm
- Errekappa Terapeutici
- EKR Therapeutics
- GlaxoSmithKline
- Johnson Johnson
- Medtronic
- Merck
- Nile
- Novartis
- Otsuka
- PeriCor
- PDL BioPharma
- Scios Inc
- Solvay Pharmaceuticals
- Sigma-Tau
- Biogen Idec
- Palatin Technologies
Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalization and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormalities occurring soon after discharge may contribute to these high post-discharge event rates. Currently available assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportunities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel approaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important goal in the management of acute heart failure syndromes. (J Am Coll Cardiol 2009; 53: 557-73) (C) 2009 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据